What is ITRMF's health score?

Iterum Therapeutics plc (ITRMF) has a TradeApes health score of 42 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ITRMF's estimated fair value?

Based on our 5-year discounted cash flow model, Iterum Therapeutics plc's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ITRMF undervalued or overvalued?

Our model currently rates ITRMF as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ITRMF... Refresh in a moment for the full analysis.

Iterum Therapeutics plc (ITRMF)

Healthcare Fair Value High weak

Updated: 2026-04-21

TradeApes Score

reduce

Financial Strength

55 Mixed

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

20 Stressed

Risk

50 Mixed

Key Findings

+ Net cash position — more cash on hand than total debt

Unlock Full Report →

− Excessive stock comp — SBC above 15% of revenue, wealth transfer to employees

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.